Related references
Note: Only part of the references are listed.Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Daniel Blanco-Melo et al.
CELL (2020)
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic
Satyajit Tripathy et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Eli S. Rosenberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Prescribing COVID-19 treatments: what we should never forget
S. Tunesi et al.
JOURNAL OF INFECTION (2020)
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
Wei Tang et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Virological assessment of hospitalized patients with COVID-2019
Roman Woelfel et al.
NATURE (2020)
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
Jia Liu et al.
CELL DISCOVERY (2020)
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
David R. Boulware et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?
Gian Marco Casillo et al.
PHARMACOLOGICAL RESEARCH (2020)
Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus
Ji Yang et al.
JOURNAL OF RHEUMATOLOGY (2018)